Esperion Therapeutics, Inc. Stock News

– Bempedoic Acid Receives Strongest Endorsement from ESC/EAS Guidelines Based on Compelling and Practice-Changing Evidence –

ANN ARBOR, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 5, 2025, the Company granted 12 new employees 73,500 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.

Esperion (ESPR) Q2 Revenue Jumps 12%

Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants Alina Venezia - Corporate Participant Benjamin Halladay - Chief Financial Officer Betty Jean Swartz - Chief Business Officer Lisa Schafer - Corporate Participant Sheldon L. Koenig - President, CEO & Director Conference Call Participants Georgia Bank - Jefferies LLC, Researc...

– Q2 2025 Total Revenue Grew 12% Y/Y to $82.4 Million – – Q2 2025 U.S. Net Product Revenue Grew 42% Y/Y to $40.3 Million – – Total Retail Prescription Equivalents Increased 10% from First Quarter – – Reached Settlement Agreements with Three ANDA Filers Not to Market Generic Versions of NEXLETOL ® (bempedoic acid) Prior to 2040 – – First Quarter of Operating Income from Ongoing Business with Pla...

ANN ARBOR, Mich., July 22, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2025 financial results before the market opens on Tuesday, August 5, 2025.

Brings More Than Twenty Years of Biopharmaceutical Leadership Experience Brings More Than Twenty Years of Biopharmaceutical Leadership Experience

Esperion's recent rebound is driven by stronger-than-expected prescription growth, revived business momentum after Medicare coverage issues subsided, and good news flow from investor conferences. Management projects profitability by Q1 2026, but I am wary given current revenue, cash, and expense guidance—profitability claims seem optimistic without a clear revenue boost. Pipeline developments, ...